GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (NAS:CLDX) » Definitions » PS Ratio

Celldex Therapeutics (Celldex Therapeutics) PS Ratio

: 281.75 (As of Today)
View and export this data going back to 1990. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Celldex Therapeutics's share price is $38.60. Celldex Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.14. Hence, Celldex Therapeutics's PS Ratio for today is 281.75.

The historical rank and industry rank for Celldex Therapeutics's PS Ratio or its related term are showing as below:

CLDX' s PS Ratio Range Over the Past 10 Years
Min: 2.54   Med: 148.87   Max: 2195.88
Current: 281.76

During the past 13 years, Celldex Therapeutics's highest PS Ratio was 2195.88. The lowest was 2.54. And the median was 148.87.

CLDX's PS Ratio is ranked worse than
91.69% of 999 companies
in the Biotechnology industry
Industry Median: 9.15 vs CLDX: 281.76

Celldex Therapeutics's Revenue per Sharefor the three months ended in Dec. 2023 was $0.08. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.14.

Warning Sign:

Celldex Therapeutics Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Celldex Therapeutics was 184.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -17.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was -34.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was -23.30% per year.

During the past 13 years, Celldex Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 327.30% per year. The lowest was -67.30% per year. And the median was -22.80% per year.

Back to Basics: PS Ratio


Celldex Therapeutics PS Ratio Historical Data

The historical data trend for Celldex Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celldex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.07 70.08 357.78 891.40 279.30

Celldex Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 891.40 545.15 491.74 299.13 279.30

Competitive Comparison

For the Biotechnology subindustry, Celldex Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celldex Therapeutics PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's PS Ratio falls into.



Celldex Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Celldex Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=38.60/0.137
=281.75

Celldex Therapeutics's Share Price of today is $38.60.
Celldex Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.14.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Celldex Therapeutics  (NAS:CLDX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Celldex Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Celldex Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Celldex Therapeutics (Celldex Therapeutics) Business Description

Traded in Other Exchanges
Address
53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
Executives
Garry Arthur Neil director 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Tibor Keler officer: Sen. VP & Ch Scientific Off. 30 PARK ROAD, OTTSVILLE PA 18942
Sarah Cavanaugh officer: SVP of Corp. Affairs & Admin. C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Diane C. Young officer: SVP, Chief Medical Officer 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
Anthony S Marucci director, officer: President and CEO 66 COLD HILL DRIVE, MENDAHM NJ 07945
Richard M. Wright officer: Sr. VP & CCO C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Samuel Bates Martin officer: SVP and CFO C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Margo Heath-chiozzi officer: SVP of of Regulatory Affairs C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Elizabeth Crowley officer: SVP, Chief Product Dev Officer C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Freddy A. Jimenez officer: SVP & General Counsel C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
James J Marino director C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Keith L Brownlie director 777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Gerald Phd Mcmahon director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114

Celldex Therapeutics (Celldex Therapeutics) Headlines

From GuruFocus